Inhibition of Platelet Aggregation and Cardiovascular Effect of 5E-13,14-Didehydro Carboprostacyclin and 5E-13,14-Didehydro-20-Methyl-Carboprostacyclin

After the discovery of prostacyclin (PGI2) in 1976 [1], the most potent inhibitor of human platelet aggregation in vitro [1] with simultaneous strong hypotensive effect in animals and humans [1, 2, 3], many efforts have been made to synthesize PGI2-derivatives that are chemically stable and which possibly have longer lasting action. The first goal has been reached easily enough and carboprostacyclin [4, 5], 10,10-difluoro-13,14-dehydroprostacyclin [6] and 16-methyl-18 yl carboprostacyclin (ZK-36374) [7] are the best known results of these efforts.